ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)
New onset diabetes and COVID-19 and: what type?
Gorchene Asma 1 , Taieb Ach 1 , Jihene Sahli 2 , Ben Abdelkarim Asma 1 , Nassim Ben Hadj Slama 1 , Hamza Elfekih 1 , Ghada Saad 1 , Molka Chadli Chaieb 1 & Koussay El Euch 1
1Farhat Hached Hospital, Endocrinology Department, Sousse, Tunisia; 2Farhat Hached Hospital, Community Medecine, Sousse, Tunisia
Introduction: During the COVID-19 pandemic, an increase of new-onset diabetes has been reported in various diabetes centers with many studies speculating an auto-immune-triggering mechanism while other studies hypothesizing an increase of type 2 diabetes (T2D).
Aim: The aim of this study is to compare the type of new-onset diabetes presenting with a diabetic ketoacidosis and its prevalence in the pre-pandemic vs pandemic COVID-19.
Methods: This is a comparative study of patients hospitalized in the diabetology department in the university hospital Farhat Hached of Sousse for a new-onset diabetic ketoacidosis in the pre-pandemic period (between March 2018 until March 2020) (G1) and 203 admitted during the pandemic period (between March 2020 until March 2022 (G2).
Results: A total of 340 patients were hospitalized in the diabetology department in the university hospital Farhat Hached of Sousse for a new-onset diabetic ketoacidosis, with 137 patients admitted in the pre-pandemic period (G1) and 203 admitted during pandemic period (G2). There was no significant difference in the prevalence of type 1 diabetes (T1D) between G1 and G2 as 54 out of 137 patients (39.41%) were T1D in G1 vs 81 out of 201 patients (40.2%) in G2. In the same way, the prevalence of T2D did not differ between the two groups with 83 out of 137 (60.5%) patients were T2D in G1 vs 120 out of 201 (59.1%) patients in G2 (P=0.871). Anti-GAD antibodies levels significantly increased during the pandemic period compared with the pre-pandemic period with a median value of 92.5 IQR [22.5-1074] in G1 vs 330 IQR [58.5-1795] in G2 (P=0.021). Anti-IA2 antibodies levels significantly increased as well during the pandemic period compared to the pre-pandemic period with a median value of 0 IQR [0-104.75] in G1 vs 93 IQR [0-3571] in G2 (P=0.009). No significant difference was found regarding anti-ZNT8 antibodies levels between the two groups (P=0.475).
Conclusion: Although the prevalence of T1D does not seem to increase during COVID-19, the increase of anti-GAD and anti-IA2 antibodies levels may reflect an increase in the intensity of auto-immune reaction of T1D during COVID-19.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more